Ventyx Biosciences: Financial Report Reveals Growth Challenges by Terry Bingman 28.03.2024 Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...
Nocion Therapeutics Secures $62M in Series B Funding by Mark Eisenberg 06.03.2024 Nocion Therapeutics raises $62M in Series B funding, bringing total funding to $122M. The biopharmaceutical company is developing small molecule ...
AI Breaks Barriers in Cancer Drug Discovery: Insilico Medicine & U of T Lead with AI-Made Molecules by Lilu Anderson 16.02.2024 Insilico Medicine and University of Toronto collaborate to target "undruggable" cancer genes using AI-designed molecules. AI is revolutionizing drug discovery ...
Accent Therapeutics secures J&J and BMS as new investors in $75M series C by Mark Eisenberg 23.01.2024 Pharmaceutical giants Bristol Myers Squibb and Johnson & Johnson invest in Accent Therapeutics, a leading RNA drug developer, contributing to ...